TAGRISSO (osimertinib mesylate): Reviews and patient testimonials


/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1720004028

Back Back to the list of medications

Medication indications

TAGRISSO 40 mg and 80 mg film-coated tablets

TAGRISSO is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC).


Route of administration: Oral
Molecule: osimertinib mesylate

Patients' opinions on TAGRISSO

In brief

General satisfaction level: 10.00/10 Learn more

Treatment's effectiveness: 10.00/10 Learn more

Ease of use: Be the first to evaluate

Adherence to prescription: 10.00/10 Learn more

Detected side effects: 1.00/10 Learn more

Improvement in the quality of life: 10.00/10 Learn more

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community


avatar
Jazmahil
on 04/01/2022

I always take mine in the afternoon with food. 

Your message

Conditions related to this medication

Fact sheet

Lung cancer

See the fact sheet